Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a Federated Electronic Medical Record Network
EHR analysis of 3,372 hospitalized COVID-19 patients not showing a significant difference for mortality or the risk of mechanical ventilation. Subject to the limitations of EHR analysis. Misclassification is possible. Confounding by indication is likely.
This study is excluded in the after exclusion results of meta
analysis:
confounding by indication is likely and adjustments do not consider COVID-19 severity at baseline.
Abstract: Federated Electronic Medical Record Network
Shailendra Singh, Ahmad Khan, Monica Chowdhry, Arka Chatterjee
Authors
Shailendra Singh M.D
1. Division of Gastroenterology, West Virginia University Health Sciences Center Charleston Division, Charleston, WV.
2. Charleston Area Medical Center Health System, Charleston, WV.
Ahmad Khan M.D
Department of Medicine, West Virginia University Health Sciences Center Charleston Division, Charleston, WV.
Monica Chowdhry M.D
Department of Medicine, West Virginia University Health Sciences Center Charleston Division, Charleston, WV.
Arka Chatterjee M.D
Division of Cardiovascular Disease, University of Alabama at Birmingham.
medRxiv preprint doi: https://doi.org/10.1101/2020.05.12.20099028; this version posted May 19, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
Outcomes of Hydroxychloroquine Treatment Among Hospitalized COVID-19 Patients in the United States- Real-World Evidence From a
Shailendra Singh M.D
Charleston Area Medical Center Health System, Charleston, WV
Email: Shail121@gmail.com
Phone no: 304-342-0821
Fax: 304-345-6679
Acknowledgment
We acknowledge the West Virginia Clinical and Translational Science Institute to provide us access, and training to the TriNETX global healthcare network.
We also acknowledge the TriNETX (Cambridge, MA, USA) healthcare network for design assistance to complete this project.
The authors received no financial support or grants for the research, authorship, and publication of this article.
Shailendra Singh, Ahmad Khan, Monica Chowdhry and Arka Chatterjee declare that they have no conflict of interest.
medRxiv preprint doi: https://doi.org/10.1101/2020.05.12.20099028; this version posted May 19, 2020. The copyright holder for this preprint
(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
It is made available under a CC-BY-NC-ND 4.0 International license .
Corresponding Author
On March 28, 2020, in response to the rapidly accelerating COVID-19 pandemic, U.S FDA issued emergency use authorization for
hydroxychloroquine (HCQ) in hospitalized COVID-19 patients based on limited in-vitro and anecdotal clinical data1,2. Analysis of the accumulated
real-world data utilizing electronic medical records (EMR) could indicate HCQ therapy benefits as we await the results of clinical trials. However,
any such analysis of retrospective observational data should account for variables such as demographics and comorbidities that could affect
treatment strategies or outcomes. Therefore, we report the outcomes of HCQ treatment in a propensity-matched cohort of COVID-19
hospitalized patients.
Methods and Findings
Using the TriNetX (Cambridge, MA, USA), a global federated health research network, we performed a real-time search and analysis of EMR of
more than 40 million patients from 34 healthcare organizations (HCOs) in the United States. TriNETX recently fast-tracked data inflow to
incorporate COVID-19 specific diagnosis and terminology following the World Health Organization (WHO) and Centers for Disease Control (CDC)
criteria. As a federated network,..
Late treatment is less effective
Please send us corrections, updates, or comments. Vaccines and
treatments are complementary. All practical, effective, and safe means should
be used based on risk/benefit analysis. No treatment, vaccine, or intervention
is 100% available and effective for all current and future variants. We do not
provide medical advice. Before taking any medication, consult a qualified
physician who can provide personalized advice and details of risks and
benefits based on your medical history and situation. FLCCC and WCH
provide treatment protocols.